Pharmacokinetics of altrenogest in gilts

J Vet Pharmacol Ther. 2019 Nov;42(6):660-664. doi: 10.1111/jvp.12755. Epub 2019 Jun 20.

Abstract

Altrenogest, a synthetic progestogen, is characterized by its estrus synchronization in mares, ewes, sows, and gilts. To investigate the pharmacokinetic profile and evaluate its accumulation in gilts, 18 oral doses of 20 mg altrenogest/gilt/day were given to eight healthy gilts at an interval of 24 hr. Plasma samples were collected, and altrenogest was determined by ultra-high-performance liquid chromatography with mass spectrometry. WinNonlin 6.4 software was used to calculate the pharmacokinetic parameters through noncompartmental model analysis. After the first administration (D 1), the pharmacokinetic parameters, including Tmax , Cmax , and the elimination half-life (T1/2λz ), were similar to those observed after the final administration (D 18). However, the mean residence time at D 1 was significantly lower than D 18. As a whole, the mean steady-state plasma concentration (Css ), degree fluctuation (DF), accumulation factor (Rac ), and area under the plasma concentration-time curve in steady state (AUCss ) were 22.69 ± 6.15 ng/ml, 270.64 ± 42.51%, 1.53 ± 0.23, and 544.63 ± 147.49 ng hr/ml, respectively. These results showed that after 18 consecutive days of oral administration of altrenogest, plasma concentrations of altrenogest had a certain degree of fluctuation, without significant accumulations.

Publication types

  • Clinical Trial, Veterinary

MeSH terms

  • Administration, Oral
  • Animals
  • Area Under Curve
  • Female
  • Half-Life
  • Progesterone Congeners / blood
  • Progesterone Congeners / pharmacokinetics*
  • Swine / blood*
  • Trenbolone Acetate / administration & dosage
  • Trenbolone Acetate / analogs & derivatives*
  • Trenbolone Acetate / blood
  • Trenbolone Acetate / pharmacokinetics

Substances

  • Progesterone Congeners
  • altrenogest
  • Trenbolone Acetate